Reactivity of the ACC-2–specific CTL clone against hematopoietic cells. (A) Cytolytic activity of CTL clone 65 against patient-derived EBV-LCLs and donor-derived EBV-LCLs loaded with ACC-2 peptide KEFEDDIINW but not against donor-derived EBV-LCLs loaded with ACC-2 control peptide KEFEDGIINW. (B) Lysis of patient-derived CML cells and leukemic cells from unrelated HLA-B44⁺, mHag ACC-2⁺ individuals but not of leukemic cells from an unrelated HLA-B44⁺, mHag ACC-2^- individual by CTL clone 65. Cytotoxicity was measured at an E/T ratio of 10:1.